Sanofi-aventis to build a vaccine facility in China

sanofi-aventisSanofi-aventis announced the signature in Beijing of an agreement between the Chinese authorities and sanofi-aventis to build a facility to manufacture influenza vaccine, during an official ceremony attended by Hu Jintao, President of the People's Republic of China, and Nicolas Sarkozy, President of the French Republic, in China for a State Visit.

This agreement was signed by Gérard Le Fur, Chief Executive Officer of sanofi-aventis and Xu Zongheng, Mayor of the Shenzhen municipality, where sanofi pasteur vaccine facility will be built. Sanofi Pasteur is the vaccines division of sanofi-aventis Group.

"China is joining a growing number of countries focusing on prevention of diseases and recognizing the value of vaccines. The time is right for sanofi pasteur to further invest in China and prepare to provide this fast growing market with the most modern vaccines to be produced in a state of the industry facility," said Gérard Le Fur, Chief Executive Officer of sanofi-aventis.

"The Shenzhen government commends this decision to invest in a Sanofi Pasteur influenza vaccine manufacturing facility in Shenzhen. It materializes 10 years of excellent collaboration between sanofi-aventis and the Shenzhen government. It is also a milestone in the history of Shenzhen biological industry development." said Xu Zongheng, Mayor of Shenzhen.

This new facility will also make it possible for sanofi pasteur to produce pandemic influenza vaccine in China in the event of a human influenza pandemic.

Sanofi Pasteur is planning to start construction of this vaccine manufacturing facility in 2008 with the goal of producing seasonal influenza vaccines for the Chinese market by 2012. This new influenza vaccine facility will be built in Shenzhen where sanofi pasteur already operates a facility. It will be designed for easy expansion to keep pace with the anticipated growth of the Chinese vaccine market.

Sanofi Pasteur's new vaccine facility in China will be designed to be able to switch to pandemic vaccine manufacturing if a human pandemic influenza is declared and once a pandemic influenza strain is identified by the World Health Organization (WHO).

With a production of 170 million doses of influenza vaccine in 2006, sanofi pasteur is the world leader in research, development and manufacture of influenza vaccines. Sanofi pasteur's Vaxigrip® and Fluzone® influenza virus vaccines are licensed in over 100 countries.

Seasonal Influenza Overview
Influenza is a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. According to the World Health Organization (WHO), 5-15% of the population is affected with upper respiratory tract infections in annual influenza epidemics. Hospitalization and deaths mainly occur in high-risk groups (elderly, people with chronic conditions/illness). Although difficult to assess, these annual epidemics are thought to result in between three and five million cases of severe illness and between 300 000 and 500 000 deaths every year around the world1. Most deaths currently associated with influenza in industrialized countries occur among the elderly over 65 years of age.
Reference: 1. www.who.int/vaccine_research/diseases/ari/en/print.html

Pandemic Influenza Overview
Influenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. An influenza pandemic is a global epidemic of an especially virulent virus, newly infectious for humans, and for which there is no preexisting immunity. This is why pandemic strains have such potential to cause severe morbidity and mortality. In an attempt to minimize the impact of a pandemic, many countries are developing national and transnational plans against a possible influenza pandemic situation.

Sanofi Pasteur and Pandemic Preparedness
Sanofi Pasteur is committed to global pandemic preparedness. As the world leader in research, development and manufacturing of influenza vaccines, sanofi pasteur is involved in pandemic preparedness projects worldwide, with the goal of developing a vaccine to protect against a pandemic influenza virus. Sanofi Pasteur is also investing in major expansions of its seasonal influenza vaccine production facilities in the U.S. and France, which could be used to produce pandemic influenza vaccine if the need arises. For more information please visit http://pandemic.influenza.com.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). For more information, please visit: www.sanofi-aventis.com.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...